05-Nov-2026 19:49:21
SYMBIOTECGeneral news
SYMBIOTEC Q2 FY27 ; CONS NET PROFIT UP 169.11% AT ₹51.73 CR (YOY), UP 268.00% (QOQ)
REVENUE UP 43.18% AT ₹279.93 CR (YOY), UP 28.32% (QOQ) EBITDA UP 81.99% AT ₹91.51 CR (YOY), UP 102.47% (QOQ) MARGINS AT 32.69% VS 25.72% (YOY), 20.72% (QOQ)
Symbiotec Pharmalab Ltd
Open attachment